Effects of Cytembena in the treatment of malignant musculoskeletal tumours.
D000179:Acrylates / Q000627:therapeutic use*; D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy*; D001943:Breast Neoplasms / Q000188:drug therapy; D001966:Bromine / Q000627:therapeutic use; D001984:Bronchial Neoplasms / Q000188:drug therapy; D002813:Chondrosarcoma / Q000188:drug therapy; D004803:Eosinophilic Granuloma / Q000188:drug therapy; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy; D005833:Genital Neoplasms, Female / Q000188:drug therapy; D005870:Giant Cell Tumors / Q000188:drug therapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D009101:Multiple Myeloma / Q000188:drug therapy; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009379:Neoplasms, Muscle Tissue / Q000188:drug therapy*; D012516:Osteosarcoma / Q000188:drug therapy; D012208:Rhabdomyosarcoma / Q000188:drug therapy; D012512:Sarcoma, Ewing / Q000188:drug therapy; D013584:Sarcoma, Synovial / Q000188:drug therapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000179:Acrylates; D000970:Antineoplastic Agents; D001565:Benzoates; D001966:Bromine